| Literature DB >> 33500591 |
Komal Zia1, Salman Ali Khan1, Sajda Ashraf1, Mohammad Nur-E-Alam2, Sarfaraz Ahmed2, Zaheer Ul-Haq1.
Abstract
The pandemic of COVID-19 has an unprecedented impact on global health and economy. The novel SARS-CoV-2 is recognized as the etiological agent of current outbreak. Because of its contagious human-to-human transmission, it is an utmost global health emergency at present. To mitigate this threat many scientists and researchers are racing to develop antiviral therapy against the virus. Unfortunately, to date no vaccine or antiviral therapeutic is approved thus there is an urgent need to discover antiviral agent to help the individual who are at high risk. Virus main protease or chymotrypsin-like protease plays a pivotal role in virus replication and transcription; thus, it is considered as an attractive drug target to combat the COVID-19. In this study, multistep structure based virtual screening of CAS antiviral database is performed for the identification of potent and effective small molecule inhibitors against chymotrypsin-like protease of SARS-CoV-2. Consensus scoring strategy combine with flexible docking is used to extract potential hits. As a result of extensive virtual screening, 4 hits were shortlisted for MD simulation to study their stability and dynamic behavior. Insight binding modes demonstrated that the selected hits stabilized inside the binding pocket of the target protein and exhibit complementarity with the active site residues. Our study provides compounds for further in vitro and in vivo studies against SARS-CoV-2.Entities:
Keywords: CAS database; COVID-19; Consensus scoring; MD simulation; SARS-CoV-2
Year: 2021 PMID: 33500591 PMCID: PMC7817485 DOI: 10.1016/j.molstruc.2021.129953
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.196
Fig. 1Structural details of 3CLPro of SARS-CoV-2. Domain organization with role of amino acid residues and 3D structure of main protease. Inter domain boundaries are labelled with amino acid residues. Domain-I shown in cyan color, Domain-II shown in hot pink color while Domain-III shown in dark purple color.
Fig. 2Schematic representation of structure-based virtual screening of CAS antiviral database.
Combination of scoring function utilized for docking.
| Placement Method | Refinement Method | Scoring Function | Rescoring Function |
|---|---|---|---|
| Triangular Matcher | Induced Fit | London dG | GBVI/WSA dG |
| Triangular Matcher | Induced Fit | London dG | ASE |
| Triangular Matcher | Induced Fit | ASE | Affinity dG |
| Triangular Matcher | Induced Fit | Alpha HB | London dG |
| Triangular Matcher | Induced Fit | Affinity dG | Alpha HB |
| Triangular Matcher | Induced Fit | London dG | Affinity dG |
| Triangular Matcher | Induced Fit | London dG | Alpha HB |
Fig. 3Time dependent RMSD of all the four simulated systems.
Fig. 4Time dependent RMSF of all the four simulated systems.
Fig. 5Time dependent RoG of all the four simulated systems.
Detailed protein-ligand interactions before and after MD simulation.
| Compound Name | Docking score (kcal/mol) | Vann der Waal Interactions After Docking | Hydrogen Bond Contacts After Docking | Vann der Waal Interactions After MD Simulation | Hydrogen Bond Contacts After MD Simulation | |||
|---|---|---|---|---|---|---|---|---|
| Acceptor | Donor | Distance | Acceptor | Donor | ||||
| SKS-01 | −11.49 | His41, Met165, Gln189 | Lig: Furan= | His41-NH | 2.18 | Thr25, Leu141 | Lig: Carbonyl= | His41-NH |
| SKS-02 | −15.32 | Thr25, Met165, Gln189 | Lig: Carbonyl= | His41-NH | 2.73 | His41, Met165, Gln189 | Lig: Hydroxyl= | Thr26: Carbonyl= |
| SKS-03 | −13.67 | Thr25, Leu27, Gln189 | Lig: Carbonyl= | His41-NH | 2.33 | His41, Met49, Met165, Gln189 | Lig: Purine-N | Asn144-NH |
| SKS-04 | −15.22 | – | Lig: Hydroxyl= | His41-NH | – | Lig: Hydroxyl= | His41-NH | |
Fig. 6Binding mode of selected hits retrieved from score based screening. (A) SKS-01, (B) SKS-02, (C) SKS-03 and (D) SKS-04. Interacting residues presented as aquamarine sticks while red dotted lines presented the hydrogen bonds.